On November 6, 2025, President Donald J. Trump announced significant developments aimed at reducing prescription drug prices through agreements with major pharmaceutical manufacturers, Eli Lilly and Novo Nordisk.

Under these agreements, prices for popular medications such as Ozempic and Wegovy, which are used to treat diabetes and obesity, will be considerably lowered when purchased through the TrumpRx program. This initiative will also permit Medicare and Medicaid to cover these medications at reduced costs, thus increasing access to treatments for chronic health conditions.

The agreements are designed not only to lower drug prices but also to encourage investment in American pharmaceutical manufacturing. Novo Nordisk has committed to a $10 billion investment to enhance its manufacturing capabilities in the United States, while Eli Lilly has pledged at least $27 billion. These investments form part of a larger strategy to strengthen the U.S. pharmaceutical supply chain and ensure that American patients benefit from lower prices on essential medications.

Additionally, President Trump emphasized the disparity in drug pricing for American patients compared to those in other developed nations, highlighting a long-standing concern regarding high U.S. drug prices. The agreements are viewed as a step towards addressing this disparity, which previously resulted in significant subsidization of drug costs for countries abroad. Through these reforms, the administration aims to fulfill its commitment to prioritize American patients and make healthcare more affordable.

Original: article